-- Ace Therapeutics, a specialized contract research organization focusing on preclinical cardiovascular research, has unveiled its full-spectrum heart disease research and drug development services to support global academic institutions and biopharmaceutical enterprises in advancing cardiovascular therapeutic innovation.
Heart disease remains one of the top global causes of mortality, accounting for 32% of all deaths worldwide. Pathological triggers including unhealthy lifestyles, genetic mutations, endothelial dysfunction, hyperlipidemia, and hypertension significantly elevate cardiovascular disease risks. Classified broadly into congenital and acquired heart diseases, conditions such as coronary atherosclerotic heart disease stand out as major research priorities in modern medical science. Leveraging decades of accumulated expertise in cardiology, Ace Therapeutics delivers integrated solutions covering basic pathological research, biomarker development, and novel drug discovery.
A core highlight of Ace Therapeutics' services lies in its professional atherosclerosis drug discovery services, which cover the entire research workflow from pathogenesis exploration and regulated cell death mechanism analysis to preclinical candidate validation. Supported by in-depth studies on fundamental regulated cell death mechanisms underlying heart disease, including apoptosis, ferroptosis, pyroptosis and autophagy-dependent cell death, the service streamlines target identification, compound screening and efficacy assessment for atherosclerosis-related drug candidates.
To facilitate reliable in vivo research and accelerate preclinical trials, Ace Therapeutics also provides tailored custom atherosclerosis animal models for researchers. These customized models are well-constructed to mimic the pathological progression of atherosclerosis, enabling accurate evaluation of drug efficacy and safety. Beyond atherosclerosis-focused services, Ace Therapeutics builds animal models and conducts research for a wide range of cardiovascular conditions, including angina pectoris, myocardial infarction, arrhythmia, heart failure, cardiomyopathy, and infectious heart diseases.
Ace Therapeutics offers one-stop outsourcing services encompassing animal model construction, pathogenesis mechanism research and novel drug development. By combining professional technical platforms and profound industry knowledge, Ace Therapeutics continues to empower clients to break through bottlenecks in heart disease research and drug development, driving the creation of more effective cardiovascular treatment options.
About Ace Therapeutics
Ace Therapeutics is a leading provider of preclinical contract research services, dedicated to supporting pharmaceutical companies, universities, and research institutions worldwide. The company’s expertise spans custom animal model development, efficacy testing, and PK/PD evaluation—all backed by state-of-the-art facilities and a team of experienced researchers. Ace Therapeutics' mission is to drive innovation in preclinical development by delivering reliable, personalized solutions that advance scientific discovery and improve global health.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/cardiovascular-diseases/
Release ID: 89193256
Google
RSS